The Asia Pacific med-tech market is projected to reach $140 billion in 2025 in value, growing roughly 5% per year, driven ...

Roche Holding AG kicked off the new year (again) with a potential $1 billion deal, including $80 million up front, for ...

As investors and industry alike try to read the tea leaves of what the upcoming change in administrations holds for the U.S., speculation abounds about what Trump 2.0 will mean for the biopharma and ...

Already hot for years, antibody-drug conjugates (ADCs) continued to hold charm for the industry, sparking a number of sizable ...

The device industry is extraordinarily dependent on administrative activity where Medicare coverage is concerned, and this ...

Altamira Therapeutics Ltd.’s nanoparticle-based delivery platform has been successfully tested for circular mRNA.

The U.K. government will unveil its 10-year health plan to transform the national health service (NHS) in the coming months. At the center of this transformation is expected to be the adoption of ...

Major depressive disorder (MDD) notched another late-stage failure in the form of Neumora Therapeutics Inc.’s data from the phase III Koastal-1 study, the first of three replicant trials in the ...

A recent study by researchers from Fudan University and Tau Cambridge Ltd. explored a novel therapeutic strategy that combines targeting CD47 with ANGPTL3, a key regulator of lipid metabolism, as a ...

The tumor microenvironment in triple-negative breast cancer (TNBC) significantly influences disease progression.

Guangdong Fapon Biopharma Inc. is developing its immunocytokine FP-008 for cancers that are refractory to anti-PD-1 therapies.

Innovent Biologics Inc. has entered into a collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd. to advance the development of IBI-3009, a novel DLL3-targeted antibody-drug ...